Printer Friendly

NEW PRODUCT OFFERS MOST PRECISE TECHNOLOGY FOR MEASURING BONE MINERAL DISEASE

 NEW PRODUCT OFFERS MOST PRECISE TECHNOLOGY
 FOR MEASURING BONE MINERAL DISEASE
 WALTHAM, Mass., Dec. 2 /PRNewswire/ -- Hologic, Inc. (NASDAQ: HOLX) announced today a new x-ray bone density measurement system, the QDR-2000, that is the most advanced technology available for monitoring and diagnosing bone mineral status. Newly developed methods of measuring bone mineral content assist physicians in diagnosing and treating conditions such as osteoporosis. The Hologic QDR-2000 has received Federal Food and Drug Administration (FDA) pre-market clearance.
 More than 25 million Americans, primarily women, suffer from osteoporosis, a condition characterized by a loss of bone mass and strength as well as an increased risk of fractures. Osteoporosis occurs in as many as two out of three women over the age of 65. Unfortunately fractures, one of the first indications of osteoporosis, often occur when the condition is in a relatively advanced stage and is more difficult to treat.
 "The goal of early prevention and treatment of osteoporosis is to identify those with low bone mass in enough time to prevent fractures from happening," said Sandra C. Raymond, executive director of the National Osteoporosis Foundation. "Bone mass measurements assist physicians in determining an individual's bone density and predict the likelihood of future fractures. Bone mass tests should always be a part of a comprehensive program of medical treatment supervised by a physician."
 The currently approved treatments for osteoporosis include estrogen replacement therapy and calcitonin, a hormone occuring naturally in the body that slows bone breakdown. New promising therapies are now under investigation by many pharmaceutical companies. Hologic QDR-2000 and QDR-1000 systems are the exclusive choice of many pharmaceutical companies and multi-center research studies to help evaluate the effectiveness of these new treatments.
 "One of the most significant features of the QDR-2000 is that it offers researchers and other physicians the capability to reproducibly perform a lateral (side-to-side) scan of the lower spine without moving the patient," said S. David Ellenbogen, president of Hologic.
 "Lateral scanning is a breakthrough and is diagnostically more sensitive than conventional postero-anterior (back-to-front) scanning to identify osteoporotic patients," said B. Lawrence Riggs, M.D., Purvis and Roberta Tabor Professor of Medical Research at the Mayo Clinic Foundation in Rochester, Minn. "The Hologic method of laterally scanning is extremely convenient and minimizes imprecision -- since the physician can move the arm of the machine for each scan, rather than having to reposition the patient," said Dr. Riggs. "The QDR-2000 offers highly sensitive measurements and allows physicians to follow patients in a more clinically meaningful manner."
 "With the QDR-2000, scan time is enhanced to as fast as five seconds compared with an average of two to five minutes with conventional systems," said Hologic President Ellenbogen. "The resultant patient comfort and improved precision of the QDR-2000 lateral scans allows a patient to be followed in a shorter interval than possible with conventional systems for bone mineral assessment."
 In the United States, the cost for a bone densitometry scan is covered by many private third party payors. The Health Care Finance Administration (HCFA) is presently reviewing scientific data to determine if reimbursement will be extended to providers treating Medicare and Medicaid patients. Earlier this year, the Blue Cross/Blue Shield Association recommended that its 73 members approve reimbursement for osteoporosis prevention.
 Consumers interested in having a scan with a Hologic QDR system can call 1-800-343-XRAY for referral to a physician or hospital in their area.
 The QDR-2000 is the third major advance in the field of osteoporosis pioneered by Hologic. The company introduced the industry's first X-ray bone densitometry machine, the QDR-1000, in 1987. An advanced system for whole body scanning, the QDR-1000/W, was introduced in 1989.
 Hologic, Inc. develops, manufactures and markets proprietary X-ray systems. With more than 800 installations worldwide, the company's QDR X-ray bone densitometers are used for the precise measurement of bone density.
 -0- 12/2/91
 /CONTACT: Joan Casey or Drew Hall of Brodeur & Partners for Hologic, Inc., 617-894-0003/
 (HOLX) CO: Hologic, Inc. ST: Massachusetts IN: MTC SU: PDT


PB-DD -- NE004 -- 8321 12/02/91 11:49 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 2, 1991
Words:671
Previous Article:TRANZONIC ACQUIRES PRESSING SUPPLY
Next Article:DU PONT NAMES VICE CHAIRMAN
Topics:


Related Articles
HOLOGIC, INC. ANNOUNCES LATEST TECHNICAL INNOVATION IN BONE DENSITOMETRY
HOLOGIC, INC. ANNOUNCES RECORD REVENUES IN FISCAL AND FOURTH QUARTER 1995
Hologic, Inc.: FDA Panel Recommends Approval with Conditions of Ultrasound Unit To Assist in the Diagnosis of Osteoporosis
Medical Data International Finds Osteoporosis Disease Management Creates Opportunities for Device Manufacturers.
GE Medical Announces Breakthrough in Nuclear Medicine Technology.
NOI GETS FDA CLEARANCE FOR TRIAL OF BONE GROWTH STIMULATOR.
BODY : RESEARCH TRIES TO LINK ZINC LEVEL, OSTEOPOROSIS.
RSNA 2005 review: Part 1.
A miniaturized, self-contained, single-use, disposable assay device for the quantitative determination of the bone resorption marker, NTx, in urine.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters